SEARCH

SEARCH BY CITATION

References

  • 1
    Starzl TE, Iwatsuki S, Vanthiel DH, Gartner JC, Zitelli BJ, Malatack JJ, Schade RR, Shaw BW Jr, Hakala TR, Rosenthal JT, Porter KA. Evolution of liver transplantation. Hepatology 1982; 2: 614636.
  • 2
    Hendrickson RJ, Karrer FM, Wachs ME, Slater K, Bak TE, Kam I. Pediatric liver transplantation. Curr Opin Pediatr 2004; 16: 309313.
  • 3
    Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, Gridelli B, Boillot O, Manzanares J, Reding R. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet 2004; 364: 10541061.
  • 4
    Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 2010; 49: 207221.
  • 5
    Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623653.
  • 6
    Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Inui K, Hori R, Inomata Y, Tanaka K, Yamaoka Y. Pharmacokinetics and pharmacodynamics of Fk-506 in pediatric-patients receiving living-related donor liver transplantations. Transplant Proc 1995; 27: 11081110.
  • 7
    Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE. Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit 2011; 33: 663672.
  • 8
    Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation 2001; 72: 10561061.
  • 9
    Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY, Ho PC. Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 2000; 50: 531541.
  • 10
    Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, Blazquez A, Manzanares J, Urruzuno P, Medina E. Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 2001; 40: 6371.
  • 11
    Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, Ogura Y, Oike F, Takada Y, Egawa H, Uemoto S, Inui K. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006; 80: 331345.
  • 12
    Hawwa AF, McElnay JC. Impact of ATP-binding cassette, subfamily B, member 1 pharmacogenetics on tacrolimus-associated nephrotoxicity and dosage requirements in paediatric patients with liver transplant. Expert Opin Drug Saf 2011; 10: 922.
  • 13
    Shuker N, Bouamar R, Weimar W, van Schaik RH, van Gelder T, Hesselink DA. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta 2012; 413: 13261337.
  • 14
    Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010; 49: 141175.
  • 15
    Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383391.
  • 16
    Morris MC, Allanby CW, Toseland P, Haycock GB, Chantler C. Evaluation of a height/plasma creatinine formula in the measurement of glomerular filtration rate. Arch Dis Child 1982; 57: 611615.
  • 17
    Lindbom L, Ribbing J, Jonsson EN. Perls-speaks-NONMEM (PsN) – a Perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 8594.
  • 18
    Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed 2011; 101: 7279.
  • 19
    Jonsson EN, Karlsson MO. Xpose – an S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 5164.
  • 20
    Anderson BJ, Woollard GA, Holford NHG. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol 2000; 50: 125134.
  • 21
    Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303332.
  • 22
    Bonate P. Pharmacokinetic-Pharmacodynamic Modeling and Simulation. New York: Springer, 2011.
  • 23
    Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263265.
  • 24
    Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, Torresani E, Edefonti A. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62: 11591169.
  • 25
    Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130137.
  • 26
    Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, Shin WG. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 2006; 26: 10691077.
  • 27
    McDiarmid SV, Colonna JO, Shaked A, Vargas J, Ament ME, Busuttil RW. Differences in oral Fk506 dose requirements between adult and pediatric liver-transplant patients. Transplantation 1993; 55: 13281332.
  • 28
    Li D, Lu W, Zhu J, Gao J, Lou Y, Zhang G. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007; 32: 505515.
  • 29
    Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009; 68: 413421.
  • 30
    Arora-Gupta N, Davies P, McKiernan P, Kelly DA. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004; 8: 145150.
  • 31
    Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, Katsura T, Ogura Y, Oike F, Takada Y, Uemoto S, Inui K. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18: 413423.
  • 32
    Pou L, Brunet M, Andres I, Rodamilans M, Lopez R, Corbella J. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int 1998; 11 (Suppl 1): S270271.
  • 33
    Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007; 64: 750757.